ABBV vs ANIK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.
ANIK's Piotroski F-Score of 2/9 indicates weak financial health, with significant red flags in profitability and cash flow. The company reports negative net income and ROE, despite a strong gross margin of 56.56%, suggesting operational inefficiencies. While the debt-to-equity ratio of 0.18 and high current ratio (4.72) point to solid liquidity, the lack of revenue growth (0% YoY) and absence of free cash flow undermine long-term sustainability. The stock trades at a forward P/E of 35.50, which is elevated relative to its lack of earnings growth, and the 63.8% 6-month rally appears speculative rather than fundamentals-driven. Analysts rate it 'strong_buy' with a target of $17.50, but this is not supported by core financial metrics.
Compare Another Pair
Related Comparisons
ABBV vs ANIK: Head-to-Head Comparison
This page compares AbbVie Inc. (ABBV) and Anika Therapeutics, Inc. (ANIK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.